Search Results

You are looking at 1 - 10 of 884 items for :

Clear All
Free access

Douglas W Strand and Andrew S Goldstein

. The regulation of these progenitors has been the subject of intense research and debate with implications for a wide range of diseases, including those of the prostate. Because of the resistance of prostate progenitor cells to current anti

Free access

Hidewaki Nakagawa

Introduction Prostate cancer (PC) is the most common malignancy in men and the second leading cause of cancer-related deaths in Western countries. Incidence and mortality rates vary widely across geographic regions and ethnic groups ( Gronberg 2003

Free access

Su Liu, Shin-Jen Lin, Gonghui Li, Eungseok Kim, Yei-Tsung Chen, Dong-Rong Yang, M H Eileen Tan, Eu Leong Yong and Chawnshang Chang

that inactivation of ARA55 inhibits the agonist effect of antiandrogens in prostate cancer (PCa) cells ( Rahman et al . 2003 ). Does increased TR4 activity induced by ARA55 inactivation play a role here? Further experiments are needed to answer this

Free access

Maho Shibata and Michael M Shen

Introduction For the past 70 years, androgen-deprivation therapy has remained the mainstay of treatment for prostate cancer. Although most prostate cancers initially respond to androgen deprivation, many will ultimately progress to lethal castration

Free access

Xinyu Wu, Shiaoching Gong, Pradip Roy-Burman, Peng Lee and Zoran Culig

Introduction Prostate cancer (PCa) is the most common male-specific cancer in most western countries including the United States. An important cause of morbidity and mortality in PCa is skeletal metastasis; the pathogenesis of bone metastasis is

Free access

Adam W Nelson, Wayne D Tilley, David E Neal and Jason S Carroll

Introduction Prostate cancer is the commonest, non-cutaneous cancer in men, affecting 214 per 1000 European men. It is the second commonest cause of cancer death, accounting for 15% of all male cancers in developed countries ( Heidenreich et al

Free access

Jamie L Van Etten and Scott M Dehm

Introduction Prostate cancer is the most frequently diagnosed cancer in men and accounts for an estimated 142,000 deaths in eveloped countries each year ( Torre et al . 2015 ). Five-year survival rates for localized diseases are high (>90

Free access

Stefano Mangiola, Ryan Stuchbery, Geoff Macintyre, Michael J Clarkson, Justin S Peters, Anthony J Costello, Christopher M Hovens and Niall M Corcoran

Introduction Prostate cancer is the most widely diagnosed cancer among men in developed countries and the second most diagnosed cancer in men worldwide ( Torre et al . 2015 ). The widespread use of serum PSA measurement as an ad hoc community

Free access

Teresa Elo, Lan Yu, Eeva Valve, Sari Mäkelä and Pirkko Härkönen

Introduction Estrogens can affect the development of the prostate and prostate tumorigenesis. Exposure to high levels of circulating estrogens during in utero development and aging has been shown to affect the prostate and may contribute to the

Free access

Isabel Coutinho, Tanya K Day, Wayne D Tilley and Luke A Selth

Introduction Prostate cancer (PCa) is the second most commonly diagnosed cancer and a leading cause of cancer-related death in men worldwide ( Ferlay et al . 2015 ). Indeed, in the USA alone, 180,890 new PCa cases are expected to be diagnosed